Gossamer Bio and Chiesi Farmaceutici (the Chiesi Group) have announced a worldwide partnership and licence agreement to develop and market seralutinib for pulmonary hypertension.

The partnership will leverage the strengths of both companies to enhance efforts in treating pulmonary arterial hypertension (PAH) and to expedite the product development for pulmonary hypertension associated with interstitial lung disease (PH-ILD).

Chiesi will offer its global expertise in respiratory and rare disease treatment, as well as inhaled drug development and commercialisation while Gossamer will contribute PAH and PH-ILD development and commercialisation teams.

Seralutinib is administered via a dry powder inhaler.

The collaboration follows the positive outcome of the Phase II TORREY clinical trial in PAH patients, prompting Gossamer to launch the Phase III PROSERA study in 2023.

The companies will begin an international Phase III registration study of seralutinib in PH-ILD by mid-2025 and are considering additional indications.

How well do you really know your competitors?

Access the most comprehensive Company Profiles on the market, powered by GlobalData. Save hours of research. Gain competitive edge.

Company Profile – free sample

Thank you!

Your download email will arrive shortly

Not ready to buy yet? Download a free sample

We are confident about the unique quality of our Company Profiles. However, we want you to make the most beneficial decision for your business, so we offer a free sample that you can download by submitting the below form

By GlobalData
Visit our Privacy Policy for more information about our services, how we may use, process and share your personal data, including information of your rights in respect of your personal data and how you can unsubscribe from future marketing communications. Our services are intended for corporate subscribers and you warrant that the email address submitted is your corporate email address.

Gossamer will head worldwide seralutinib development for PAH and PH-ILD indications.

Development expenditures will be shared, other than for the PROSERA study, which remains Gossamer’s financial responsibility.

Commercial profits and losses incurred in the US will be divided equally between the companies, with Gossamer handling commercialisation and sales booking for PAH and PH-ILD.

Gossamer Bio and Chiesi will contribute equally to the product’s commercial efforts.

Chiesi will handle the US commercialisation works for any additional indications and exclusively commercialise seralutinib outside the US.

In return, the company will make royalty payments to Gossamer on net product sales.

The agreement stipulates a $160m development reimbursement to Gossamer from Chiesi, along with potential regulatory and sales-based milestone payments of $146m and $180m respectively.

Gossamer co-founder, chairman and CEO Faheem Hasnain stated: “This partnership with Chiesi allows us to meaningfully deepen and rapidly accelerate our investment in seralutinib as a potential treatment for PAH, PH-ILD and other indications of high unmet medical need.

“We are particularly thrilled that this collaboration enables seralutinib to move directly into a Phase III trial in PH-ILD, an indication with a paucity of available treatments, and a disease which we believe seralutinib is specifically designed to address.”